Secukinumab
- PDF / 169,798 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 11 Downloads / 155 Views
1
S
Ulcerative colitis: case report A 36-year-old woman developed ulcerative colitis during treatment with secukinumab for ankylosing spondylitis (AS). The woman, who was diagnosed with AS, initially treated with sulfasalazine [salazopyrin]. However, no response was achieved. Thus, after receiving sulfasalazine for 6 months, she started receiving secukinumab [dosage and route not stated]. She received first five secukinumab once weekly and subsequent doses were given once monthly for 4 months. Her inflammatory back pain regressed following secukinumab therapy. Eventually, she was hospitalised due to bloody diarrhoea (10 times daily for 2 weeks). Although, serological tests for diarrhoea were negative. Colonic mucosas were hyperaemic, vascular structure was lost, there were ulcers in all visible colon segments. Her sigmoid colon biopsy suggestive of ulcerative colitis [duration of treatment to reaction onset not stated]. The woman was then treated with methylprednisolone and sulfasalazine. Following steroid treatment, bloody diarrhoea regressed. Her general condition improved, and she was discharged with weekly outpatient control. Author comment: "Pathogenesis of secukinumab induced [ulcerative colitis] is not konwn exactly. Secukinumab treatment related [ulcerative colitis] attack is a rare advers affect." Polat YH, et al. A rare cause of inflammatory bowel disease: Secukinumab. Turkish Journal of Gastroenterology 30 (Suppl. 3): S183-S184 abstr. PP-27, Sep 2019. Available from: URL: http://doi.org/10.5152/tjg.2019.050919 [abstract] 803436922 Turkey
0114-9954/19/1781-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 30 Nov 2019 No. 1781
Data Loading...
